



■ TEL. : 022 - 6825 2525
■ FAX : 022 - 2405 7708
■ E-Mail : info@naxparlab.com
■ Visit us at: www.naxparlab.com
■ CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

Date: 09th November, 2023

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001.

Sub: Outcome of Board Meeting under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Ref: Submission of Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th September, 2023 in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.

Ref: Parnax Lab Limited, Script Code- 506128

Dear Sir,

Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., **Thursday, 09th November, 2023** at its Registered Office, the Board inter alia has transacted the following business:

1. Considered and Approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and half year ended 30th September, 2023, along with Limited Review Report thereon.

A Copy of Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and half year ended 30th September, 2023, along with Limited Review Report thereon, pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2015, is enclosed herewith.

The aforesaid information and Financial Results are being made available on the Company's website at www.naxparlab.com



■ TEL. : 022 - 6825 2525
■ FAX : 022 - 2405 7708
■ E-Mail : info@naxparlab.com
■ Visit us at: www.naxparlab.com
■ CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

The meeting of the Board of Directors Commenced at 5.00 P.M. and Concluded at 06.15 P.M.

Kindly take on your record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

For Parnax Lab Limited

PREET VIJAY
KUKREJA

Digitally signed by
PREET VIJAY
KUKREJA
Date: 2023.11.09
18:09:51 +05'30'



Preet Kukreja
Company Secretary & Compliance Officer
ACS No.: 56761

Encl: As above



C. N. PATEL & CO.
Chartered Accountants

Plot No. 12, Aradhana, State Bank Colony,
Opp. Tidke Vidyalaya, Katol Road, Nagpur - 440013.
Tel. No. +91 712 2584800, 9922584800
Email ID : info@cnpca.in : www.cnpca.in

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULT

To The Board of Directors of Parnax Lab Limited,

1. We have reviewed the unaudited standalone financial results of **Parnax Lab Limited** ("the Company") for the quarter and six month ended September 30, 2023 which are included in the accompanying "Statement of Unaudited Standalone Financial Results for the quarter and six month ended September 30, 2023" together with the relevant notes thereon ("the Statement"). The statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") read with SEBI Circular No. CIR/CFD/FAC /62/2016 dated July 05, 2016.
2. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. The Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that cause us to believe that the accompanying Statement of unaudited standalone financial result has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For C N Patel & Co
Chartered Accountants
(Firm Regd. No. 112552W)

(Manish Mandhana)

Partner

M. No. 112026

UDIN : **23112026BGVHDO2923**

Place: Mumbai

Date: 9th November, 2023



PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com
CIN-L36912MH1982PLC027925


STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2023

(Rs. in Lakhs)

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Unaudited)	30.09.2023 (Unaudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
I	Revenue from operations	183.21	113.23	75.66	296.44	386.97	747.38
II	Other income	18.10	11.48	2.69	29.58	10.53	37.08
III	Total Revenue (I+II)	201.31	124.71	78.35	326.02	397.50	784.46
IV	Expenses						
	a) Cost of material consumed	67.73	41.41	35.64	109.14	88.23	188.52
	b) Purchase of stock in trade	34.32	27.30	15.32	61.62	133.60	158.96
	c) Changes in inventories of finished goods, Work in progress and stock in trade	(37.13)	-	-	(37.13)	-	-
	d) Employee benefit expenses	17.49	14.21	13.71	31.70	27.42	55.21
	e) Finance costs	7.31	3.58	4.96	10.89	15.53	24.89
	f) Depreciation and amortisation expenses	1.82	1.08	1.13	2.90	2.24	6.78
	g) Other expenses	30.75	28.19	16.92	58.94	84.52	187.41
	Total Expenses (IV)	122.29	115.77	87.67	238.06	351.54	621.77
V	Profit/(loss) before exceptional items and tax (III-IV)	79.02	8.94	(9.32)	87.96	45.96	162.69
VI	Exceptional items	-	-	-	-	-	-
VII	Profit/(loss) before tax (V-VI)	79.02	8.94	(9.32)	87.96	45.96	162.69
VIII	Tax expense						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	19.34	2.29	(5.15)	21.63	9.11	42.24
	c) Short (Excess) provision for tax for earlier years	-	-	-	-	-	-
IX	Profit/ (loss) for the period (VII-VIII)	59.68	6.65	(4.17)	66.33	36.85	120.45
X	Other comprehensive income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	(6.78)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	1.71
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XI	Total other comprehensive income for the period	-	-	-	-	-	(5.07)
XII	Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)	59.68	6.65	(4.17)	66.33	36.85	115.38
XIII	Paid-up equity share capital (Face Value of the share Rs. 10)	1,148.56	1,148.56	1,148.56	1,148.56	1,148.56	1,148.56
XIV	Earning per equity share (Not annualised)						
	(1) Basic	0.52	0.06	(0.04)	0.58	0.32	1.05
	(2) Diluted	0.52	0.06	(0.04)	0.58	0.32	1.05

Notes-

- The Financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 09, 2023.
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and half year ended September 30, 2023.
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment - Dealing in Pharmaceutical Formulations
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.



By Order of the Board
For Parnax Lab Limited

Prakash M Shah

Prakash M Shah
Director & CEO
DIN : 00440980

Place : Mumbai
Date : 09-11-2023

PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com
CIN:-L36912MH1982PLC027925

Statement of Assets and Liabilities as at 30th September, 2023

(Rs. in Lakhs)

S. No.	Particulars	Standalone		
		30.09.2023 (Unaudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
A	ASSETS			
1	Non-Current Assets			
(a)	Property, plant and equipment	51.54	41.92	42.53
(b)	Capital work-in-progress	-	-	-
(c)	Investment Property	-	-	-
(d)	Other Intangible assets	0.09	0.06	0.10
(e)	Financial assets			
(i)	Investments	1,003.08	1,006.95	1,003.08
(ii)	Other non-current financial assets	0.25	0.25	0.25
(f)	Deferred tax assets (net)	45.40	98.44	67.04
2	Current Assets			
(a)	Inventories	71.49	18.02	57.57
(b)	Financial assets			
(i)	Investments	-	-	-
(ii)	Trade Receivables	59.79	99.21	107.97
(iii)	Cash and cash equivalents	87.25	38.03	126.64
(iv)	Bank balances other than above	1.55	1.35	1.55
(v)	Loans	413.20	258.59	293.08
(c)	Current tax assets (Net)	1.67	0.23	1.61
(d)	Other current assets	52.06	106.96	61.14
(e)	Assets classified as held for sale	372.00	374.05	374.05
	TOTAL - ASSETS	2,159.37	2,044.05	2,136.61
B	EQUITY AND LIABILITIES			
1	Equity			
(a)	Equity share capital	1,148.56	1,148.56	1,148.56
(b)	Other equity	853.18	708.32	786.86
2	Liabilities			
(I)	Non-current liabilities			
(a)	Financial liabilities			
(i)	Borrowings	-	62.54	16.08
(b)	Provisions	0.95	0.76	0.95
(c)	Deferred tax liabilities (Net)	-	-	-
(d)	Other non - current liabilities	-	-	-
(II)	Current liabilities			
(a)	Financial liabilities			
(i)	Borrowings	63.07	86.52	91.07
(ii)	Trade payables			
- total outstanding dues of micro enterprises and small enterprises		33.65	7.32	30.97
- total outstanding dues of creditors other than micro enterprise and small enterprise		18.96	8.22	12.37
(iii)	Other current financial liabilities	34.64	19.67	37.05
(b)	Other current liabilities	6.16	1.12	12.50
(c)	Short-term provisions	0.20	1.02	0.20
	TOTAL EQUITY AND LIABILITIES	2,159.37	2,044.05	2,136.61



By Order of the Board
For Parnax Lab Limited

(Signature)

Prakash M Shah
Director & CEO
DIN : 00440980

Place : Mumbai
Date : 09-11-2023

PARNAX LAB LIMITED

Standalone Cash Flow Statement for the period ended 30th September, 2023

(Rs. in Lakhs)

Particulars	For the period ended 30th September, 2023	For the period ended 30th September, 2022	For the year ended 31st March 2023
	(Unaudited)	(Unaudited)	(Audited)
A. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit/(Loss) before tax	87.96	45.97	162.69
Adjustments for			
Depreciation	2.90	2.24	6.78
Finance Costs	10.89	15.53	24.90
Loss on sale of Property, plant & equipments			-
Sundry Balances written off	0.02	0.00	1.14
Interest & Dividend income	(14.84)		(15.29)
Operating Loss Before Working Capital Adjustments	86.93	63.74	180.22
Changes in Working Capital			
<u>Adjustments for (increase) / decrease in operating assets:</u>			
Inventories	(13.92)	61.47	21.92
Trade receivables	48.18	86.74	77.97
Other assets (Financials and Non Financial assets)	(111.04)	(245.49)	(234.16)
-			-
<u>Adjustments for increase / (decrease) in operating liabilities:</u>			
Trade payables	9.25	(98.95)	(72.28)
Other liabilities (Financials and Non Financial assets)	(8.75)	(21.71)	(0.38)
Cash generated from operations	10.65	(154.20)	(26.71)
Direct Tax Paid (Refund) [Net]	0.06	0.08	1.45
Net cash flow from / (used in) operating activities (A)	10.59	(154.28)	(28.16)
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of property, plant & equipment	(19.86)	-	(5.19)
Proceeds from sale of fixed assets	10.00	-	(0.21)
Proceeds/(Purchase) from sale of Non Current Investments	-	-	3.88
Interest & Dividend income	14.84		15.29
Net cash flow from / (used in) investing activities (B)	4.98	-	13.77
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Issue of Shares, Warrants	-	545.08	545.08
Proceeds from long-term borrowings (net)	(16.08)	(52.20)	(98.66)
Proceeds from Short-term borrowings (net)	(27.99)	(718.33)	(713.78)
Finance Cost	(10.89)	(15.53)	(24.90)
Net cash flow from / (used in) financing activities (C)	(54.96)	(240.98)	(292.26)
Net increase (decrease) in cash and cash equivalents (A+B+C)	(39.39)	(395.26)	(306.65)
Cash and cash equivalents at the beginning of the year	126.64	433.29	433.29
Cash and cash equivalents at the end of the year	87.25	38.03	126.64



By Order of the Board
For Parnax Lab Limited

Prakash M Shah

Prakash M Shah
Director & CEO
DIN : 00440980

Place : Mumbai
Date : 09-11-2023



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULT

TO THE BOARD OF DIRECTORS OF

Parnax Lab Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Parnax Lab Limited** ("the Parent") and its subsidiary Naxpar Pharma Private Limited (the Parent and its subsidiary together referred to as "the Group") for the quarter and six month ended September 30, 2023, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Naxpar Pharma Private Limited - Subsidiary


5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. We did not review the interim financial statements of Naxpar Pharma Private Limited, subsidiary respectively included in the consolidated unaudited financial results, whose interim financial statements reflect total assets of Rs. 15,070.57 lakhs as at September 30, 2023 and total revenues of Rs. 8,912.98 lakhs, total net profit after tax of Rs. 453.74 lakhs and total comprehensive income of Rs. 453.74, for the quarter and six month ended September 30, 2023 respectively, as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by the other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on the reports of the other auditors and the procedure performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For C N Patel & Co
Chartered Accountants
(Firm Regd. No. 112552W)


(Manish Mandhana)

Partner

M. No. 112026

UDIN: **23112026BGVHDP8811**

Place: Mumbai

Date: 09th November, 2023



PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

CIN:-L36912MH1982PLC027925

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2023

(Rs. in Lakhs)

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Unaudited)	30.09.2023 (Unaudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
I	Revenue from operations	4,261.15	4,874.18	4,313.88	9,135.33	7,987.81	16,760.69
II	Other income	22.30	24.44	29.54	46.74	41.79	77.22
III	Total Revenue (I+II)	4,283.45	4,898.62	4,343.42	9,182.07	8,029.60	16,837.91
IV	Expenses						
	a) Cost of material consumed	2,292.07	2,692.88	2,250.10	4,984.95	4,029.50	8,864.79
	b) Purchase of stock in trade	41.11	27.86	22.38	68.97	80.86	70.00
	c) Changes in inventories of finished goods, Work in progress and stock in trade	(170.89)	32.84	40.74	(138.05)	17.31	(53.37)
	d) Employee benefit expenses	576.42	568.13	493.34	1,144.55	959.86	2,005.30
	e) Finance costs	142.97	115.71	120.21	258.68	246.44	495.10
	f) Depreciation and amortisation expenses	173.84	160.18	154.72	334.02	320.34	652.90
	g) Other expenses	993.88	902.95	950.92	1,896.83	1,812.74	3,575.22
	h) Impairment of assets classified as held for disposal						
	Total Expenses (IV)	4,049.40	4,500.55	4,032.41	8,549.95	7,467.05	15,609.94
V	Profit/(loss) before exceptional items and tax (III-IV)	234.05	398.07	311.01	632.12	562.55	1,227.97
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	234.05	398.07	311.01	632.12	562.55	1,227.97
VIII	Tax expense						
	a) Current Tax	17.00	88.00	70.69	105.00	129.00	304.00
	b) Deferred Tax	29.87	(22.81)	29.98	7.06	29.98	79.75
	c) Short (Excess) Prov for Tax for Earlier Years	-	-	-	-	-	(19.08)
IX	Profit/ (Loss) for the period (VII-VIII)	187.18	332.88	210.34	520.06	403.57	863.30
X	Minority Interest Profit (Loss)	0.26	0.65	0.43	0.91	0.73	1.48
XI	Profit/ (Loss) after share of Profit (Loss) of Minority Interest	186.92	332.23	209.91	519.15	402.84	861.82
XII	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	(13.80)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	3.66
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XIII	Total Other Comprehensive Income for the period	-	-	-	-	-	(10.14)
XIV	Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)	187.18	332.88	210.34	520.06	403.57	853.16



[Handwritten Signature]

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Unaudited)	30.09.2023 (Unaudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
XV	Total profit/(loss) for the year attributable to:						
	- Owners of the Company,	186.92	332.23	209.90	519.15	402.84	861.82
	- Non-controlling interests	0.26	0.65	0.43	0.91	0.73	1.48
XVI	Other Comprehensive income attributable to :						
	- Owners of the Company		-		-	-	(10.13)
	- Non-controlling interests		-		-	-	(0.01)
XVII	Total Comprehensive income attributable to:						
	- Owners of the Company	186.92	332.23	209.90	519.15	402.84	851.69
	- Non-controlling interests	0.26	0.65	0.43	0.91	0.73	1.47
XVIII	Paid-up equity share capital (Face Value of the share Rs. 10)	1,148.56	1,148.96	1,148.56	1,148.56	1,148.56	1,148.96
XIX	Earning per equity share (Not Annualised)						
	(1) Basic	1.63	2.90	1.83	4.53	3.51	7.51
	(2) Diluted	1.63	2.90	1.83	4.53	3.51	7.51

Notes-

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as ammended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 09, 2023.
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and half year ended September 30, 2023.
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

Place : Mumbai
Date : 09-11-2023



By Order of the Board
For Parnax Lab Limited

(Signature)

Prakash M Shah
Director & CEO
DIN NO: 00440980

PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

CIN:-L36912MH1982PLC027925

Statement of Consolidated Assets and Liabilities as at 30th September, 2023

(Rs. in Lakhs)

S. No.	Particulars	Consolidated		
		30.09.2023 (Unaudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
A	ASSETS			
1	Non-Current Assets			
(a)	Property, plant and equipment	7,918.13	6,668.72	7,285.91
(b)	Right-of-use asset	908.89	324.13	371.41
(c)	Capital work-in-progress	73.69	546.06	232.99
(d)	Other Intangible assets	19.70	18.42	23.31
(e)	Financial assets			
(i)	Investments	16.08	22.46	16.08
(ii)	Other non-current financial assets	91.91	52.36	58.18
(f)	Deferred tax assets (net)			
(g)	Other non-current assets	179.73	296.10	413.06
2	Current Assets			
(a)	Inventories	2,608.94	2,182.62	2,168.69
(b)	Financial assets			
(i)	Trade Receivables	2,910.36	3,079.69	2,789.26
(ii)	Cash and cash equivalents	89.19	48.06	127.95
(iii)	Bank balances other than above	134.87	156.06	150.15
(iv)	Loans	21.01	44.36	42.67
(c)	Current tax assets (Net)	18.24	16.79	18.17
(d)	Other current assets	410.67	476.85	435.41
(e)	Assets classified as held for sale	372.00	374.05	374.05
	TOTAL - ASSETS	15,773.41	14,306.73	14,507.29
B	EQUITY AND LIABILITIES			
1	Equity			
(a)	Equity share capital	1,148.56	1,148.56	1,148.56
(b)	Other equity	5,586.00	4,618.00	5,066.85
	Equity attributable to owner	6,734.56	5,766.56	6,215.41
	Non Controlling Interest	11.58	9.93	10.67
	Total Equity	6,746.14	5,776.49	6,226.08
2	Liabilities			
(I)	Non-current liabilities			
(a)	Financial liabilities			
(i)	Borrowings	1,101.69	1,407.01	1,202.38
(ii)	Lease Liabilities	876.89	287.43	331.08
(b)	Provisions	20.79	29.48	50.82
(c)	Deferred tax liabilities (Net)	399.83	346.66	392.77
(II)	Current liabilities			
(a)	Financial liabilities			
(i)	Borrowings	3,885.32	4,184.81	3,887.62
(ii)	Trade payables			
- total outstanding dues of micro enterprises and enterprises		417.71	499.31	510.05
- total outstanding dues of creditors other than enterprise and small enterprise		1,340.58	874.93	966.30
(iii)	Lease Liabilities	39.38	44.86	50.83
(iv)	Other current financial liabilities	831.91	719.31	752.35
(b)	Other current liabilities	55.62	39.03	79.16
(c)	Short-term provisions	23.20	9.46	23.20
(d)	Current Tax Liability (net)	34.35	87.95	34.65
	Total Liability	9,027.27	8,530.24	8,281.21
	TOTAL EQUITY AND LIABILITIES	15,773.41	14,306.73	14,507.29

By Order of the Board
For Parnax Lab Limited




Prakash M Shah
Director & CEO
DIN NO: 00440980

Place : Mumbai
Date : 09-11-2023

PARNAX LAB LIMITED
Consolidated Cash Flow Statement for the period ended 30th September, 2023

(Rs. in Lakhs)

Particulars	For the period ended 30th September, 2023 (Unaudited)	For the period ended 30th September, 2022 (Unaudited)	For the year ended 31st March 2023 (Audited)
A. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit/(Loss) before tax	632.12	562.56	1,227.97
Adjustments for			
Depreciation	334.02	320.34	652.91
Finance Cost	258.68	246.44	495.10
Loss /(Profit) on sale of Property, plant & equipments	(0.78)	(1.15)	(1.16)
Lease Modification	(3.13)	-	-
Sundry Balances written off	(0.06)	(0.29)	22.75
Interest & Dividend income	(2.09)	(5.04)	(11.26)
Operating Loss Before Working Capital Adjustments	1,218.77	1,122.86	2,386.31
Changes in Working Capital			
<u>Adjustments for (increase) / decrease in operating assets:</u>			
Inventories	(440.25)	(189.78)	(175.85)
Trade receivables	(121.10)	727.85	1,081.10
Other assets (Financials and Non Financial assets)	115.82	101.01	21.34
<u>Adjustments for increase / (decrease) in operating liabilities:</u>			
Trade payables	281.92	(833.25)	(795.40)
Other liabilities (Financials and Non Financial assets)	26.00	(262.67)	(140.04)
Cash generated from operations	1,081.16	666.02	2,377.46
Direct Tax Paid (Refund) [Net]	105.47	41.11	286.45
Net cash flow from / (used in) operating activities (A)	975.69	624.91	2,091.01
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of property, plant & equipment	(983.27)	(160.70)	(1,128.03)
Expenditure on capital work in progress	159.29	(211.82)	101.25
Expenditure on asset held for disposal	-	-	-
Investment in fixed deposit	15.28	(14.18)	(8.26)
Proceeds from sale of fixed assets	34.00	25.00	25.00
Proceeds/(Purchase) from sale of Non Current Investments	-	-	6.39
Interest & Dividend income	2.09	5.04	11.26
Net cash flow from / (used in) investing activities (B)	(772.61)	(356.66)	(992.39)
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Issue of Shares, Warrants	-	545.08	545.08
Proceeds from long-term, borrowings (net)	(100.69)	(334.05)	(538.68)
Proceeds from short-term, borrowings (net)	117.54	(620.99)	(918.18)
Finance Cost	(258.68)	(246.44)	(495.10)
Net cash flow from / (used in) financing activities (C)	(241.84)	(656.40)	(1,406.88)
Net increase (decrease) in cash and cash equivalents (A+B+C)	(38.76)	(388.15)	(308.26)
Cash and cash equivalents at the beginning of the year	127.95	127.95	436.21
Cash and cash equivalents at the end of the year	89.19	(260.20)	127.95

Place : Mumbai
Date : 09-11-2023



By Order of the Board
For Parnax Lab Limited

Prakash M Shah
Prakash M Shah
Director & CEO
DIN : 00440980